APAC IPOs & Placements, Aequitas Research

Nicholas Tan

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Aequitas: Cofoe Medical IPO Trading - Weak Insti Subs but Cheaper than Peers

Aequitas: Cofoe Medical Technology A/H Listing - Recovering from Post-Pandemic Slump

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Cofoe Medical Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cofoe-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:45716:1" rel="noopener">Cofoe Medical Technology (CFMT HK)</a> is looking to raise up to US$135m in its upcoming Hong Kong IPO.</li>
<li>It was founded in 2009 (with its brand tracing back to 2007), and as per the prospectus, is a leading provider of home care medical devices in China. </li>
<li>In this note, we examine the IPO dynamics, and look at the firm’s valuation.</li>
</ul>



Cofoe Medical Technology (CFMT HK) is looking to raise up to US$135m in its upcoming Hong Kong IPO.
It was founded in 2009 (with its brand tracing back to 2007), and as per the prospectus, is a leading provider of home care medical devices in China. 
In this note, we examine the IPO dynamics, and look at the firm’s valuation.


Aequitas: Cofoe Medical A/H Listing - Discount to HK and International Med-Device Peers